$4.66
5.96% today
Nasdaq, Sep 19, 05:48 pm CET
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Vanda Pharmaceuticals Inc. Stock price

$4.95
-0.40 7.48% 1M
+1.20 32.00% 6M
+0.73 17.30% YTD
+0.49 10.99% 1Y
-11.54 69.98% 3Y
-8.24 62.47% 5Y
-7.45 60.08% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
+0.01 0.20%
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Key metrics

Market capitalization $288.53m
Enterprise Value $-90.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 16.41
EV/Sales (TTM) EV/Sales -0.50
P/S ratio (TTM) P/S ratio 1.59
P/B ratio (TTM) P/B ratio 0.53
Revenue growth (TTM) Revenue growth -23.63%
Revenue (TTM) Revenue $182.02m
EBIT (operating result TTM) EBIT $-32.47m
Free Cash Flow (TTM) Free Cash Flow $-5.53m
Cash position $387.68m
EPS (TTM) EPS $-0.19
P/E forward negative
P/S forward 1.43
EV/Sales forward negative
Short interest 6.86%
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
33%
Hold
67%

Financial data from Vanda Pharmaceuticals Inc.

Assets
Jun '24
439 439
Cash 388 388
Claims 42 42
Inventories 1.47 1.47
Other current assets Other current assets Current assets 8.17 8.17
212 212
Property, plant and equipment 8.68 8.68
Financial assets 0.47 0.47
Intangible Assets 118 118
Other fixed assets Other assets Fixed assets 85 85
Total Assets 651 651
Liabilities
Jun '24
Equity 543 543
109 109
Current liabilities 94 94
Non-current liabilities 15 15
Total Capital 651 651

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Negative
Reuters
about 4 hours ago
The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals' drug to treat stomach paralysis symptoms, the company said on Thursday.
Neutral
PRNewsWire
about 5 hours ago
WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program.
Neutral
PRNewsWire
8 days ago
WASHINGTON , Sept. 11, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2024 Cantor Global Healthcare Conference in New York City on Thursday, September 19, 2024.
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 203
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today